Results 221 to 230 of about 282,737 (397)

Foot-and-Mouth Disease control costs compared: An Irish case study. [PDF]

The primary objective of this paper is to evaluate alternative control strategies for a number of simulated outbreaks of Foot-and-Mouth Disease (FMD) in four agriculturally diverse Irish regions, examining for the first time, the potential role of ...
Dillon, Emma J., Matthews, Alan, Thorne, Fiona S.   +2 more
core   +1 more source

Pre‐admission beta‐blocker therapy and outcomes in cardiogenic shock: Insights from the Altshock‐2 Registry

ESC Heart Failure, EarlyView.
Among 668 with cardiogenic shock included in the multicentre prospective Altshock‐2 registry, 299 patients (44.8%) received pre‐admission beta‐blocker therapy. Previous beta‐blocker therapy influenced the early hemodynamic response to vasoactive drugs, but it was not associated with in‐hospital mortality.
Matteo Pagnesi, Mauro Riccardi, Alice Sacco, Giovanni Tavecchia, Giovanna Viola, Simone Frea, Martina Briani, Letizia Fausta Bertoldi, Maurizio Bertaina, Luciano Potena, Serafina Valente, Marco Marini, Gaetano Maria De Ferrari, Nicoletta D'Ettore, Astrid Cardinale, Rita Camporotondo, Matteo Rota, Guido Tavazzi, Nuccia Morici, Federico Pappalardo, Marco Metra, on behalf of the Altshock‐2 investigators   +21 more
wiley   +1 more source

Correction: Effective inhibition of foot-and-mouth disease virus (FMDV) replication in vitro by vector-delivered microRNAs targeting the 3D gene

Virology Journal, 2023
Junzheng Du, Shandian Gao, Jihuai Luo, Guofeng Zhang, Guozheng Cong, Junjun Shao, Tong Lin, Xuepeng Cai, Huiyun Chang   +8 more
doaj   +1 more source

Foot-and-mouth disease reproduction number: a scoping review. [PDF]

Front Vet Sci
Gunasekera U, VanderWaal K, Arzt J, Perez A.   +3 more
europepmc   +1 more source

Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology

European Journal of Heart Failure, EarlyView.
For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a ...
Maurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, Pier Giuseppe Agostoni, Javed Butler, Andrew J.S. Coats, Alan Cohen‐Solal, Wolfram Doehner, Gerasimos Filippatos, Ewa Jankowska, Carolyn S.P. Lam, Ekaterini Lambrinou, Lars H. Lund, Giuseppe Rosano, Marco Metra, Stefania Paolillo, Pasquale Perrone Filardi, Amina Rakisheva, Gianluigi Savarese, Petar Seferovic, Carlo Gabriele Tocchetti, Massimo Piepoli   +21 more
wiley   +1 more source

Spatio-temporal dynamics of hand, foot and mouth disease in Malaysia, 2009-2019. [PDF]

PLoS Negl Trop Dis
Cox VM, Jahis R, Abu Bakar RS, Yusof NM, Pilay KPV, Chem YK, Selvanesan S, Shamsudin N, Hinsley W, Blake IM, Hasran NZ, Rusli N, Sam IC, Chan YF, Pons-Salort M.   +14 more
europepmc   +1 more source

Cross-Cultural Awareness: Good Manners, Taboos, and Foot-in-Mouth Disease [PDF]

, 1988
Lindenau, Suzanne E.
core   +2 more sources

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

CD44 mediates the internalization of foot-and-mouth disease virus through macropinocytosis. [PDF]

Vet Res
Wang X, Dong H, Wu J, Zhang Y, Sun S, Guo H.   +5 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source